Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q12923
UPID:
PTN13_HUMAN
Alternative names:
Fas-associated protein-tyrosine phosphatase 1; PTP-BAS; Protein-tyrosine phosphatase 1E; Protein-tyrosine phosphatase PTPL1
Alternative UPACC:
Q12923; B2RTR0; Q15159; Q15263; Q15264; Q15265; Q15674; Q16826; Q8IWH7; Q9NYN9; Q9UDA8
Background:
Tyrosine-protein phosphatase non-receptor type 13, also known as Fas-associated protein-tyrosine phosphatase 1, PTP-BAS, Protein-tyrosine phosphatase 1E, and Protein-tyrosine phosphatase PTPL1, plays a crucial role in cellular signaling. It negatively regulates FAS-induced apoptosis and NGFR-mediated pro-apoptotic signaling, and may influence phosphoinositide 3-kinase (PI3K) signaling through dephosphorylation of PIK3R2.
Therapeutic significance:
Understanding the role of Tyrosine-protein phosphatase non-receptor type 13 could open doors to potential therapeutic strategies.